Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase III Results for Crusekitug in Ankylosing Spondylitis
Qyuns Therapeutics Co., Ltd. announced that the Phase III clinical trial results for Crusekitug (QX002N), a drug developed for the treatment of ankylosing spondylitis, were presented at the 2025 annual meeting of the American College of Rheumatology (ACR Convergence) in Chicago. The multicenter, randomized, double-blind, placebo-controlled study involved 641 patients across 58 research centers in China. The trial demonstrated that at week 16, the ASAS40 response rate in the Crusekitug group was 40.4%, compared to 18.9% in the placebo group, with statistical significance (P < 0.0001). The ASAS20 response rate for Crusekitug was 65.2%, also significantly higher than the placebo group. The study included a 48-week treatment period and a 4-week safety follow-up.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。